| Patient | Mumtaz Mahal |
|---|---|
| Date of birth | 1593-04-27 |
| Identifiers | MRN HR-RE006-SYN-TD; SSN (made up) 000-06-7184 |
| Document date | 1631-04-14 |
| Author | Farzana Qureshi-Lindholm, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Prenatal visit at 27 weeks. [S]
Mumtaz Mahal returns at 27 weeks 2 days. The cystitis three weeks ago settled within two days of starting nitrofurantoin, and the culture grew Escherichia coli sensitive to it; she finished the 5-day course. She has no urinary symptoms now. She feels well, with good energy, and the baby moves often. She takes aspirin and folic acid. She has no headache, visual change, swelling of the face or hands, abdominal pain, contractions, bleeding, or leaking fluid. Her family plans to travel for about six weeks, starting next week, mostly by road, and she intends to go with them. [S]
| Element | Detail |
|---|---|
| Cystitis | Resolved; culture Escherichia coli, sensitive to nitrofurantoin; course completed |
| Energy | Good since the second iron dose |
| Fetal movement | Frequent |
| Travel | About six weeks of road travel planned from next week |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Well; energy good |
| Cardiovascular | Negative | No breathlessness, palpitations, or leg swelling |
| Neurological | Negative | No headache or visual change |
| Genitourinary | Negative | No urinary symptoms, bleeding, or leaking fluid |
| Psychiatric | Negative | Mood steady; EPDS 6 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Folic acid 0.4 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1631-01-06 | active | S |
| Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other day | One tablet every other morning with water or orange juice, apart from tea and calcium | Oral route | 1631-01-06 to 1631-02-03 | completed | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime | One tablet by mouth at bedtime until delivery | Oral route | 1631-01-06 | active | S |
| Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily for 5 days | One capsule twice daily with food for 5 days | Oral route | 1631-03-24 to 1631-03-29 | completed | S |
| Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (first of two doses) | Single infusion; two doses in total, four weeks apart | Intravenous route | 1631-02-03 to 1631-02-03 | completed | S |
| Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (second of two doses) | Single infusion; two doses in total, four weeks apart | Intravenous route | 1631-03-03 to 1631-03-03 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1631-04-14 | Body height | 157 | cm | S |
| 1631-04-14 | Body weight | 64.6 | kg | S |
| 1631-04-14 | Body mass index (BMI) [Ratio] | 26.2 | kg/m2 | S |
| 1631-04-14 | Systolic blood pressure | 108 | mm[Hg] | S |
| 1631-04-14 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1631-04-14 | Heart rate | 86 | /min | S |
| 1631-04-14 | Respiratory rate | 16 | /min | S |
| 1631-04-14 | Body temperature | 36.7 | Cel | S |
| 1631-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1631-04-14 | Hemoglobin [Mass/volume] in Blood | 11.4 | g/dL | 10.5-15 g/dL | Normal | S |
| 1631-04-14 | Ferritin [Mass/volume] in Serum or Plasma | 110 | ng/mL | 30-150 ng/mL | Normal | S |
| 1631-04-14 | Platelets [#/volume] in Blood by Automated count | 232 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1631-04-14 | Glucose [Mass/volume] in Serum or Plasma --1 hour post 50 g glucose PO | 128 | mg/dL | <=139 mg/dL | Normal | S |
| 1631-04-14 | Total score [EPDS] | 6 | {score} | S |
Vital signs recorded on 1631-04-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Abdomen | Fundal height 27 cm; non-tender |
| Fetal | Fetal heart 144 per minute by Doppler |
| Extremities | No edema; calves soft and non-tender |
| Urine dipstick | Protein negative; leukocytes and nitrite negative |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Fourteenth pregnancy at 37 (gravida 14, para 13), single live intrauterine pregnancy dated by ultrasound at 13 weeks 2 days; estimated due date July 12 | active | confirmed | O09.529 | S — Synthetic modern prenatal care anchored to her documented fourteenth pregnancy; the dates are synthetic. |
| Grand multiparity: thirteen previous vaginal births, no cesarean or other uterine surgery; seven living children | active | confirmed | O09.40 | S — Synthetic modern problem anchored to her documented thirteen earlier births. |
| Short interpregnancy interval: conception about five and a half months after her last birth | active | confirmed | O09.899 | S — Synthetic modern problem anchored to the documented fourteen months between her last two births. |
| Iron deficiency anemia in pregnancy: hemoglobin 10.1 g/dL, MCV 76 fL, ferritin 9 ng/mL | active | confirmed | O99.019 | S — Synthetic finding; repeated pregnancies close together deplete iron. It echoes no documented diagnosis. |
| Acute cystitis in pregnancy at 24 weeks: dysuria and frequency, no fever or flank pain; urine culture grew Escherichia coli sensitive to nitrofurantoin; treated and resolved | resolved | confirmed | O23.12 | S — Synthetic intercurrent infection at an unscheduled visit; common in pregnancy and in multiparous women. It echoes no documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and urine protein | Every prenatal visit | Completed today | 108/68 mmHg; urine protein negative |
| Examination | Fetal heart and fundal height | Every prenatal visit | Completed today | Fetal heart 144 per minute; fundal height 27 cm |
| Examination | Weight gain | Every prenatal visit | Completed today | 64.6 kg, up 6.0 kg since intake |
| Laboratory | Hemoglobin and ferritin | At intake, four weeks after starting treatment, at 24 to 28 weeks, and before delivery | Completed today | Hemoglobin 11.4 g/dL and ferritin 110 ng/mL |
| Laboratory | Gestational diabetes screen (one-hour 50 g glucose challenge) | At 24 to 28 weeks | Completed today | 128 mg/dL, below the 140 mg/dL threshold |
| Laboratory | Urine culture as a test of cure after cystitis | One to two weeks after treatment | Ordered | Sent today, two weeks after the course ended |
| Laboratory | Antibody screen and anti-D at 28 weeks | At 28 weeks for RhD-negative patients | Not indicated | RhD positive with a negative antibody screen at intake |
| Medication safety | Tdap vaccine | Once at 27 to 36 weeks in every pregnancy | Completed today | Given today |
| Medication safety | Low-dose aspirin | Daily from 12 to 16 weeks until delivery; review at every visit | Completed today | Taken nightly; no bruising or bleeding |
| Survey | Perinatal mood screen (EPDS) | Each trimester | Completed today | 6; item 10 scored 0 |
| Self-management | Travel planning | Before any travel in pregnancy | Completed today | Six weeks of road travel planned; records given; care to be arranged where she stays |
| Self-management | Postpartum hemorrhage risk assessment and birth plan | At intake, in the third trimester, and on admission for birth | Up to date | Anemia corrected; grand multiparity remains; detailed plan at the next visit |
Goal progress:
Immunizations given today: Tdap vaccine in pregnancy, 27 weeks [S]
Guideline basis: Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022); Anemia in Pregnancy: ACOG Practice Bulletin, Number 233 (2021); Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021); ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus (2018); ACOG Committee Opinion No. 746: Air Travel During Pregnancy (2018); Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America (2019)
Follow-up: Prenatal visits at 30 and 32 weeks where she is staying, then here on her return. Next scheduled visit 1631-06-02: prenatal visit at 34 weeks: growth scan, postpartum hemorrhage risk assessment, delivery plan, and contraception counseling. [S]